Phreesia, Inc. $PHR Shares Bought by Bosun Asset Management LLC

Key Points

• Bosun Asset Management LLC increased its investment in Phreesia, Inc. by 110.5% in Q1, bringing its total stock position to $571,000.
• Phreesia has received multiple analyst upgrades, maintaining a consensus rating of "Buy" with an average target price of $32.54.
• Insider trading activity saw significant sales, with insiders selling 119,874 shares worth approximately $3.59 million in the last three months.

Bosun Asset Management LLC boosted its position in shares of Phreesia, Inc. (NYSE:PHR - Free Report) by 110.5% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 22,335 shares of the company's stock after acquiring an additional 11,724 shares during the quarter. Bosun Asset Management LLC's holdings in Phreesia were worth $571,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. KBC Group NV purchased a new stake in shares of Phreesia in the first quarter worth about $74,000. CWM LLC raised its position in Phreesia by 994.9% during the first quarter. CWM LLC now owns 4,040 shares of the company's stock valued at $103,000 after acquiring an additional 3,671 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in Phreesia by 53.0% in the first quarter. Smartleaf Asset Management LLC now owns 5,267 shares of the company's stock valued at $137,000 after acquiring an additional 1,825 shares during the period. Tower Research Capital LLC TRC boosted its position in Phreesia by 1,023.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,660 shares of the company's stock worth $142,000 after purchasing an additional 5,156 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of Phreesia by 10,605.7% during the 1st quarter. GAMMA Investing LLC now owns 5,674 shares of the company's stock worth $145,000 after purchasing an additional 5,621 shares during the period. 92.10% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Phreesia

In related news, General Counsel Allison C. Hoffman sold 1,245 shares of the company's stock in a transaction that occurred on Thursday, July 17th. The stock was sold at an average price of $26.89, for a total value of $33,478.05. Following the sale, the general counsel owned 136,978 shares of the company's stock, valued at approximately $3,683,338.42. This represents a 0.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Evan Roberts sold 3,400 shares of Phreesia stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $32.46, for a total value of $110,364.00. Following the sale, the insider owned 724,368 shares of the company's stock, valued at approximately $23,512,985.28. This represents a 0.47% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 109,292 shares of company stock worth $3,295,323. 5.50% of the stock is currently owned by insiders.

Phreesia Trading Down 1.4%

Shares of PHR traded down $0.38 during trading on Tuesday, reaching $26.41. 526,758 shares of the company traded hands, compared to its average volume of 567,721. The stock has a 50-day simple moving average of $28.31 and a 200-day simple moving average of $26.50. The stock has a market cap of $1.57 billion, a PE ratio of -62.84 and a beta of 0.72. Phreesia, Inc. has a twelve month low of $17.07 and a twelve month high of $32.76. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.02.

Phreesia (NYSE:PHR - Get Free Report) last issued its earnings results on Thursday, September 4th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.08. Phreesia had a negative return on equity of 9.00% and a negative net margin of 5.35%.The business had revenue of $117.26 million for the quarter, compared to analyst estimates of $116.39 million. During the same quarter last year, the company earned ($0.03) EPS. The business's quarterly revenue was up 14.9% on a year-over-year basis. Phreesia has set its FY 2026 guidance at EPS. On average, analysts anticipate that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Raymond James Financial set a $33.00 target price on shares of Phreesia and gave the company an "outperform" rating in a research note on Friday. KeyCorp lifted their price objective on shares of Phreesia from $28.00 to $35.00 and gave the company an "overweight" rating in a report on Monday, July 14th. Mizuho started coverage on shares of Phreesia in a research note on Wednesday, August 27th. They set an "outperform" rating and a $36.00 target price on the stock. Truist Financial upped their price target on Phreesia from $35.00 to $36.00 and gave the stock a "buy" rating in a report on Friday. Finally, Canaccord Genuity Group increased their target price on Phreesia from $34.00 to $38.00 and gave the company a "buy" rating in a research report on Friday. One analyst has rated the stock with a Strong Buy rating and twelve have assigned a Buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $34.08.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.